SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), through its subsidiary GlucaPharm Inc., is advancing GEP-44, a patented triple agonist peptide targeting GLP-1 and peptide YY receptors, as the global obesity and metabolic disease market continues to expand rapidly. The company is pursuing a differentiated approach focused on improved efficacy, tolerability, and delivery flexibility in a therapeutic category that has become one of the most commercially significant in modern healthcare, with long-term market projections exceeding $200 billion.
Industry momentum continues accelerating as major pharmaceutical companies advance next-generation obesity and diabetes therapies through new formulations, expanded indications, and reduced-frequency dosing strategies aimed at improving patient access and adherence. While large-cap incumbents dominate the current market with blockbuster GLP-1 products, SureNano is positioning itself as an emerging microcap participant focused on preclinical innovation, alternative delivery technologies, and broader platform opportunities that may extend beyond metabolic disease therapeutics.
SureNano is part of an increasingly competitive GLP-1 landscape led by Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN), and Pfizer Inc. (NYSE: PFE). The company's GEP-44 candidate aims to differentiate itself through improved tolerability and potential non-injectable delivery, which could address key barriers to patient adherence in obesity treatment.
SureNano Science Ltd. is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing global health markets. The company has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP-44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery, as detailed in a press release dated February 23, 2026.
The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano™ surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity, and taste. The company has an exclusive license to distribute the SureNano™ surfactant within Canada; Oklahoma, USA; and Colorado, USA. SureNano Science Ltd. is now developing into a pharmaceutical focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease.
For more information, visit https://ibn.fm/g3EkQ and the company's newsroom at https://ibn.fm/SURNF.
